Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 3, 2007, Pages 507-516

  Goessens, W H F ^a   Mouton, J W ^b   ten Kate, M T ^a   Bijl, A J ^a   Ott, A ^a   Bakker Woudenberg, I A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Collateral damage; Mutant selection window; Mutation prevention concentration; PK PD indices

Indexed keywords

BETA LACTAMASE; CEFOXITIN; CEFTAZIDIME; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTERIUM MUTANT; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; ENTEROBACTER CLOACAE; ENTEROBACTER INFECTION; ENZYME ACTIVITY; ENZYME ASSAY; FECES CULTURE; INOCULATION; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; RAT; ANIMAL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; GENOTYPE; INTESTINE; LUNG DISEASE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; GENOTYPE; INTESTINES; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; RATS;

EID: 34248155761     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl529     Document Type: Article

References (34)

1. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 Suppl 3): S233-7.
2. Flynn DM, Weinstein RA, Nathan C et al. Patients' endogenous flora as the source of 'nosocomial' Enterobacter in cardiac surgery. J Infect Dis 1987; 156: 363-8.
3. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136 834-44.
4. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7.
5. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15: 279-91.
6. Muller A, Lopez-Lozano JM, Bertrand X et al. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004; 54: 173-7.
7. de Man P, Verhoeven BAN, Verbrugh HA et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-8.
8. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29(Suppl A): 19-24.
9. Liu Y, Cui J, Wang R et al. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: Concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 2005; 56: 1172-5.
10. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-17.
11. Dong Y, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus auteus. Antimicrob Agents Chemother 1999; 43: 1756-8.
12. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
13. Bakker-Woudenberg IA, van den Berg JC, Michel MF. Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 1982; 22: 1042-50.
14. Bakker-Woudenberg IAJM, ten Kate MT, Goessens WHF et al. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 2006; 50: 2919-25.
15. Paterson DL, Rice LB, Bonomo RA. Rapid method of extraction and analysis of extended-spectrum β-lactamases from clinical strains of Klebsiella pneumoniae. Clin Microbiol Infect 2001; 7: 709-11.
16. O'Callaghan CH, Morris A, Kirby SM et al. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1972; 1: 283-8.
17. Lu T, Zhao X, Li X et al. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 2003; 52: 61-4.
18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998; 26 1-12.
19. Peterson LR. Squeezing the antibiotic balloon: The impact of antimicrobial class on emerging resistance. Clin Microbiol Infect 2005; 11 (Suppl 5): 4-16.
20. Perlman DC, El Sadr WM, Heifets LB et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-8.
21. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39: 219-26.
22. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33(Suppl 3): S147-56.
23. Campion JJ, McNamara PJ, Evans ME. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 2004; 48: 4733-44.
24. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994; 38: 409-14.
25. Allen GP. The mutant prevention concentration (MPC): A review. J Infect Dis Pharmacother 2003; 6: 27-47.
26. Blondeau JM, Hansen G, Metzler K et al. The role of PK/PD parameters to avoid selection and increase of resistance: Mutant prevention concentration. J Chemother 2004; 16(Suppl 3): 1-19.
27. Hansen GT, Blondeau JM. Mutant prevention concentration as a strategy to minimize antimicrobial resistance: A timely concept but will its acceptance be too late? Therapy 2005; 2: 61-6.
28. Etienne M, Croisier D, Charles PE et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190 1472-5.
29. Cui J, Liu Y, Wang R et al. The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194: 1601-8.
30. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the mutant selection window. J Infect Dis 2002; 185: 561-5.
31. Olofsson SK, Marcusson LL, Komp Lindgren P et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: Relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57: 1116-21.
32. Olson B, Weinstein RA, Nathan C et al. Broad-spectrum β-lactam resistance in Enterobacter: Emergence during treatment and mechanisms of resistance. J Antimicrob Chemother 1983; 11: 299-10.
33. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother 2001; 48: 463-78.
34. Paterson DL. 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(Suppl 4): S341-5.